Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Lyka Labs Ltd

LYKALABS

Lyka Labs Ltd

LYKALABS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹532 cr, stock is ranked 1,810
High RiskStock is 3.70x as volatile as Nifty
149.274.21% (-6.56)
149.274.21% (-6.56)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹532 cr, stock is ranked 1,810
High RiskStock is 3.70x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹532 cr, stock is ranked 1,810
High RiskStock is 3.70x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
887.917.68—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.1%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.03%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue146.54112.3265.3972.8766.3387.81196.1796.72112.64120.09
Raw Materialssubtract67.9055.7827.5835.8036.4634.9153.3838.7645.64102.09
Power & Fuel Costsubtract1.391.901.862.282.562.943.923.603.93
Employee Costsubtract14.7117.2416.9814.6913.8614.5718.0618.6126.77
Selling & Administrative Expensessubtract16.476.338.7611.309.007.5713.9212.7116.05
Operating & Other expensessubtract17.6510.209.399.7538.247.7110.1710.193.50
Depreciation/Amortizationsubtract9.3210.2511.287.318.018.3217.3514.1512.8011.09
Interest & Other Itemssubtract15.1918.729.587.1720.0725.9420.1311.874.894.19
Taxes & Other Itemssubtract0.21-2.57-2.77-9.87-1.33-2.6020.240.041.562.12
EPS1.70-2.51-6.88-1.98-21.31-4.0313.59-4.45-0.780.18
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Lyka Labs Ltd-213.107.68—
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare LYKALABS with any stock or ETF
Compare LYKALABS with any stock or ETF
LYKALABS
Loading...

Shareholdings

Promoter Holdings Trend

Increased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 3.29%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.22%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding58.10%0.01%0.66%0.15%41.08%

Mar 2024

Apr 2024

Jun 2024

Sep 2024

Shareholding History

SepDec '23MarAprJunSep0.18%0.17%0.17%0.16%0.15%0.15%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

LYKALABS has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 11 October 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Lyka Labs reports consolidated net profit of Rs 1.44 crore in the June 2024 quarter

Net profit of Lyka Labs reported to Rs 1.44 crore in the quarter ended June 2024 as against net loss of Rs 1.85 crore during the previous quarter ended June 2023. Sales rose 31.60% to Rs 30.11 crore in the quarter ended June 2024 as against Rs 22.88 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.1122.88 32 OPM %12.3211.54 - PBDT3.621.67 117 PBT1.86-1.80 LP NP1.44-1.85 LP Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Lyka Labs to convene AGM

Lyka Labs announced that the Annual General Meeting (AGM) of the company will be held on 9 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Lyka Labs Consolidated September 2023 Net Sales at Rs 27.99 crore, up 9.64% Y-o-Y

1 year agoMoneycontrol

Lyka Labs Standalone June 2023 Net Sales at Rs 21.24 crore, down 2.93% Y-o-Y

1 year agoMoneycontrol

Stocks that will see action on March 22, 2023

1 year agoThe Hindu Businessline

Kohinoor Foods Ltd leads losers in ‘B’ group

1 year agoBusiness Standard

Lyka Labs shares jump 5% on signing pact to buy Agilis’ animal healthcare business

1 year agoBusiness Today